Low expression of PRAL is reportedly associated with poor prognosis in non-small cell lung cancer [108], a finding similar to that in a more recent study showing that low PRAL expression in the malignant cells of multiple myeloma, especially those with 17p deletion, correlated with significantly shorter disease-free and overall survival [105]. Here, PRAL is linked to non-small cell lung carcinoma.